Panelists discuss why elinzanetant is likely to be associated with a lower risk of liver injury due to its distinct molecular structure compared to fezolinetant, and compare the adverse event profiles of the 2 drugs, highlighting that elinzanetant is more commonly associated with headache and fatigue while fezolinetant is linked to abdominal pain, diarrhea, insomnia, and back pain.
Panelists discuss why a warning about serious liver injury was added to the prescribing information for fezolinetant following a postmarketing case of drug-induced liver injury, and review updated guidelines for baseline liver testing, recommended monitoring, symptoms indicating the need to discontinue the medication, and key points for addressing patient concerns about liver health.
Panelists discuss how to simplify the physiology of KNDy neurons and neurokinin (NK) receptors for primary care physicians, explaining how NK3 antagonism reduces hot flashes, while NK1 antagonism helps alleviate sleep disturbances and night sweats, with fezolinetant and elinzanetant serving as key nonhormonal treatment options.
Kameelah Phillips, MD, FACOG, NCMP, discusses how advances in molecular testing have improved the diagnosis and management of vaginitis and sexually transmitted infections like Mycoplasma genitalium and trichomoniasis, emphasizing the importance of education and awareness to promote better screening practices.
Discover how innovative self-collection methods and the BD Onclarity HPV assay are breaking barriers in cervical cancer screening, empowering underserved communities with accessible and accurate care.
Dr Coffman breaks down the findings from the phase III MIRASOL trial, and provides insight surrounding the treatment options and potential clinical implications surrounding ovarian cancer treatment.
Panelists discuss how neurokinin 3 (NK3) receptors contribute to vasomotor symptoms (VMS) and how antagonism of NK3 receptors with drugs like fezolinetant can effectively reduce VMS, while also exploring the dual receptor action of elinzanetant, which blocks both NK1 and NK3 receptors to improve VMS and associated sleep disturbances.
Panelists discuss how KNDy neurons, which coexpress kisspeptin, neurokinin B (NKB), and dynorphin genes, play a crucial role in hormonal reproduction and the development of vasomotor symptoms (VMS) in menopause.
Jean Dubuisson, MD, PhD, head of the gynecological surgery unit at Geneva University Hospitals, discusses the first successful hysterectomy performed using the MIRA surgical system.
The March of Dimes 2024 report reveals a troubling D+ grade for US preterm births, with significant racial and socioeconomic disparities fueling an urgent need for better prenatal care and targeted interventions.
Learn why postpartum hemorrhage remains a critical maternal health issue in the United States and discover effective treatment approaches and preventative strategies shared by expert ob-gyn Kameelah Phillips, MD.
Rossella Nappi, MD, PhD, highlights how fezolinetant rapidly reduces the severity and frequency of hot flashes, offering a personalized, non-hormonal solution for menopausal women.
Discover how cutting-edge artificial intelligence technologies are enhancing early breast cancer detection, improving accuracy, and personalizing care for better patient outcomes.
Discover the unique cardiovascular risks women face compared to men, and learn how proactive screening and partnerships between cardiologists and ob-gyns can improve women's heart health.
Learn how early detection, patient education, and personalized risk assessments can help ob-gyns support women in reducing the impact of breast cancer.
Ruth M Carrico, PhD, DNP, APRN, discusses the significance of the FLUBLOK vaccine's updated label, offering pregnant patients a safe and effective alternative for influenza prevention.
In this 4-part interview, Kingsberg discusses the phase 2 RECONNECT trial assessing RE104 as the potentially first psychedelic to treat postpartum depression.
A new study shows that breast arterial calcification detected on routine mammograms could help predict cardiovascular events such as heart attacks and strokes, particularly in younger women.
Erika Hamilton, MD, discusses concerning increases in breast cancer incidence among younger women and certain ethnic groups, while highlighting new innovations in detection and targeted therapies that offer hope for improved patient outcomes.
Elinzanetant, a non-hormonal drug, shows promising results in reducing hot flashes and night sweats, offering a new option for women seeking effective and safe treatment for vasomotor symptoms.
Matthew Nudy, MD, discusses his team's findings on hormone therapy and cardiovascular effects at the 2024 Annual Meeting of the Menopause Society.
Learn how self-advocacy, preparation, and collaboration with doctors can help women gain control over their health and live more fully, free from stigma and shame.
Discover how deepening understanding and providing vetted resources can empower women to reclaim their wellness and navigate the powerful impacts of menopause with confidence.
Fezolinetant offers women a groundbreaking, non-hormonal solution to manage menopause symptoms like hot flashes and sleep disturbances, supported by large clinical trials.
Research reveals that environmental exposures and PTSD from Gulf War service significantly increase the likelihood of early menopause, highlighting the need for targeted reproductive health care for women veterans.
Vanessa Muñiz presents research comparing clinical hypnosis and cognitive behavioral therapy for treating hot flashes, revealing that hypnosis significantly reduces frequency and improves quality of life.
Stephanie Faubion, MD, MBA, medical director of the Menopause Society, shares details from her presentation on hormone therapy at the 2024 Annual Meeting of The Menopause Society.
Lauren Streicher, MD, advocates for practical, individualized solutions for postmenopausal sexual dysfunction, emphasizing increased vascularization, stimulation, and addressing related symptoms.
The phase 3 OASIS trial presented at the 2024 Annual Meeting of The Menopause Society displayed significant improvements in the frequency of moderate-to-severe vasomotor symptoms among patients receiving elinzanetant.
